In a significant leap forward for emergency medical response and biosecurity, Atlanta-based Micron Biomedical has secured a $4.5 million contract from the National Institute of Allergy and Infectious Diseases (NIAID). The funding, awarded under the institute’s prestigious Radiation and Nuclear Countermeasures Program, marks a pivotal moment in the development of "dissolvable" drug delivery systems. By integrating its proprietary microarray patch (MAP) technology with Connext’s therapeutic TLR5 agonist, xempritolimod, Micron is positioning itself to revolutionize how we treat Acute Radiation Syndrome (ARS)—a condition characterized by severe, life-threatening injury following high-dose radiation exposure.
This partnership is not merely a technical collaboration; it represents a fundamental shift in the logistics of crisis management. By replacing traditional, cold-chain-dependent, and skill-intensive needle injections with a simple, self-administered "push-button" patch, the medical community is moving toward a future where critical care can be delivered in the most austere environments, from the center of a radiation disaster to the heart of a remote, resource-deprived village.
The Core Innovation: A Technological Paradigm Shift
The technology behind Micron Biomedical’s solution traces its roots back to the pioneering research of Dr. Mark Prausnitz at the Georgia Institute of Technology. Co-founded by Prausnitz alongside industry veterans Devin McAllister and Sebastien Henry, the company has spent years refining the science of microneedle delivery.
At its simplest level, the microarray patch is a medical device that looks like a small adhesive bandage. However, the underside is embedded with a forest of microscopic, dissolvable projections. Unlike traditional hypodermic needles that pierce deep into the tissue and strike nerve endings—resulting in pain and requiring medical training for safe disposal—Micron’s patches target only the upper, superficial layers of the skin.
The manufacturing process is as innovative as the device itself. Micron formulates a drug into a liquid solution, which is then cast into a micro-molded template. Through a precise vacuum-assisted process, the liquid is pulled into the microscopic cavities, ensuring no air bubbles remain. Once dried, the drug solidifies into the needle structure, creating a thermostable, long-lasting medication carrier. The patch is then finished with a protective backing layer, ready to be pressed against the skin of a patient.
Chronology of Development: From Lab Bench to Federal Contract
The journey to the $4.5 million NIAID contract is the culmination of years of rigorous validation.
- Foundational Years: The technology originated in the Georgia Tech labs of Dr. Mark Prausnitz, where the concept of a painless, dissolvable delivery mechanism was first proven viable.
- Proof of Concept: Micron Biomedical secured initial funding and partnerships to refine the scalability of the technology, moving from academic prototypes to robust, manufacturable devices.
- Clinical Validation: A landmark study published in The Lancet provided crucial clinical evidence for the platform. In a trial testing influenza vaccines, the patch demonstrated numerically higher seroconversion rates—a primary marker of immune response—compared to traditional intramuscular injections. While the findings were not statistically significant in that specific cohort, the 71% seroconversion rate for the B strain (compared to 32% for injection) turned heads across the pharmaceutical industry.
- Pandemic Preparedness: Recognizing the platform’s potential, the Coalition for Epidemic Preparedness Innovations (CEPI) entered a partnership with Micron to apply this technology to rapid-response vaccine platforms, specifically targeting "Disease X" threats.
- July 2026: The official announcement of the $4.5 million NIAID contract solidified Micron’s role as a key player in the national biosecurity infrastructure, moving the company from a promising biotech startup to a government-vetted medical supplier.
Supporting Data and Efficacy
The skepticism often associated with non-traditional delivery methods is being systematically addressed by Micron’s clinical data. The primary argument against traditional injections in emergency settings is not just the pain, but the "cold chain"—the requirement to keep drugs refrigerated from the factory to the patient.
Micron’s patches are thermostable. This feature is a game-changer for stockpiling. Because the drug is stabilized within the solid matrix of the microneedles, the patches can be stored at room temperature for extended periods. In the event of a radiological disaster, authorities would not need to worry about the degradation of life-saving drugs due to power outages or broken supply chains.
Furthermore, the data suggests that for certain therapeutics, the skin may be a superior site for administration. Because the skin is rich in immune cells, delivering a vaccine or a drug directly to the dermal layer can trigger a more robust systemic response than dumping a large volume of liquid into the muscle. The 2017 Lancet data serves as a cornerstone of this argument, demonstrating that the patch is not just an alternative to the needle, but potentially a more efficient method of delivery.
Official Perspectives: The Vision of CEO Steven Damon
In an exclusive interview with Drug Discovery and Development, Micron Biomedical CEO Steven Damon emphasized the operational necessity of this technology.
"If something happened, we’d be able to quickly get it to that location and to those people, and they’d be able to self-administer it," Damon said. "It would allow a fast response."
For Damon, the "button" on the patch is the ultimate equalizer. By removing the need for a physician, a nurse, or a sterile clinic environment, the barrier to care vanishes. He paints a vision of the future where these patches are kept in every household, every emergency vehicle, and every stockpile across the globe.
"It’s the first delivery system like this in the world; nothing like it existed before," Damon added, noting that while the technology has limitations regarding the total volume (dose) of drug it can deliver, it is perfectly suited for the vast majority of potent, modern biological therapeutics.
Regarding the company’s roadmap, Damon is focused on domestic manufacturing. "The key to improving that timeline was building out manufacturing… we actually had to invent the equipment, and that equipment is being built domestically." He anticipates that the first commercial products will be available within the next two years, with a phased approach that starts with smaller, specialized applications before scaling to more widespread use.
Implications for Global Health and Biosecurity
The implications of Micron’s platform extend far beyond the immediate goal of treating ARS.
1. Democratizing Access to Medicine
In low-income nations, the "last mile" of medical delivery is often the hardest. Lack of electricity, lack of trained medical personnel, and the challenges of transporting liquid vials make mass vaccination campaigns difficult. Micron’s patches could be transported via moped into the most remote villages, where an untrained parent could safely administer a vaccine to their child. This capability has the potential to eliminate entire categories of vaccine-preventable diseases in developing regions.
2. Pandemic Readiness
The COVID-19 pandemic highlighted the fragility of global supply chains. The ability to stockpile millions of doses of a vaccine or treatment at room temperature—without the need for massive, specialized freezer farms—could save governments billions of dollars and provide a much more agile response to future outbreaks.
3. The Future of Chronic Care
Beyond emergencies, Micron is eyeing the massive market for injectable weight-loss medications and chronic disease therapies. The ability to replace a weekly or daily syringe with a simple, painless patch could significantly improve patient compliance, as the primary reason for treatment abandonment in many chronic conditions is the fear or discomfort associated with needles.
4. A New Standard for Biosecurity
The collaboration with the NIAID is an explicit recognition by the U.S. government that traditional medical supply chains are inadequate for the modern threat landscape. By investing in Micron’s platform, the government is building a "plug-and-play" infrastructure that can be adapted to any number of CBRN (Chemical, Biological, Radiological, and Nuclear) threats.
Conclusion
As Micron Biomedical moves toward its goal of bringing the first products to market by 2028, the company remains focused on two primary pillars: scaling production and diversifying its portfolio. By proving the efficacy of its technology through the lens of national security, the company is establishing the credibility necessary to disrupt the broader pharmaceutical delivery market.
The era of the "sharps-free" future is no longer a distant theoretical concept; it is an active, funded, and rapidly developing reality. As the company continues to work with the FDA to validate its platform, the world watches with anticipation. If Micron can successfully navigate the complexities of manufacturing and regulatory approval, the simple act of receiving medicine will be transformed—from a clinical procedure into an effortless, everyday interaction.
About the Author
